Peak COVID-19 season is on its way, and this year there’s a wrinkle: the vaccines are here, but the federal guidance about who should get them is a mess.
Here’s the good news. The updated 2026-2027 vaccines were approved on August 27, 2026; they target the strain that’s actually circulating right now, and here in New York, access is more protected than it’s been in two years — thanks to state law, not federal policy.
The less-than-stellar news is that the federal advisory committee that normally tells providers and insurers who’s eligible hasn’t been able to meet since March. That doesn’t change the science. It does change the paperwork.
Read on for what’s new this year, your brand options, when to get vaccinated, and what the access situation actually looks like on the ground.
In This Article:
- COVID-19 review: What we know
- What’s new this year with the COVID vaccine?
- The 2026 guidance situation, explained
- What this means for New Yorkers
- Who should and who shouldn’t get the COVID-19 vaccine
- The best time to get the COVID vaccine
- COVID-19 vaccine side effects and efficacy
PLEASE NOTE: We research and reference this information, but also express opinions of the experienced professionals of Village Apothecary. We are pharmacists, but we may not be YOUR pharmacist. Do not make any medical decisions without first contacting your primary care provider.
COVID-19 Disease and Vaccine Review: What We Know
You probably know this already, but it never hurts to refresh our understanding of COVID-19 and the importance of prevention.
COVID-19 is caused by a coronavirus called SARS-CoV-2, which spreads quickly from person to person. SARS-CoV-2 can cause symptoms ranging from mild or moderate illness lasting only a few days to severe illness requiring hospitalization, intensive care, or a ventilator to help with breathing. COVID-19 can also result in death.
COVID-19 vaccines like Comirnaty, Spikevax, mNEXSPIKE, and Nuvaxovid are designed to help prevent COVID-19 and to help reduce the severity of symptoms if you do get sick.
Learn More: Vaccines Do Work, But They’re Not Perfect
What’s New This Year? 2026-2027 COVID Vaccine Updates
This year’s vaccines target XFG. On May 28, 2026, the FDA’s advisory committee (VRBPAC) voted to build this season’s vaccine around the XFG variant — nicknamed “Stratus” — and the FDA adopted that recommendation the next day. XFG is a recombinant variant still descended from the JN.1 branch of the Omicron family tree.
Worth noting: the World Health Organization went a different direction, recommending LP.8.1 for its member countries. That kind of split isn’t unusual. WHO guidance has to work for the whole world; the FDA is looking specifically at what’s circulating in the United States. And in the U.S., XFG and its descendants (like XFG.1.1) have been the dominant players for months.
The vaccines are approved and shipping. On August 27, 2026, the FDA approved the 2026-2027 formulas across the board.
COVID isn’t waiting for fall. As of August 2026, wastewater surveillance is showing a real summer wave — SARS-CoV-2 concentrations roughly doubled from July to August nationally. This is your annual reminder that COVID is not seasonal the way flu is.
Federal recommendations are in limbo. More on this below, because it deserves its own section.
All four approved products target XFG. None of them is preferred over another.
| Vaccine | Manufacturer | Platform | FDA-approved ages |
| Comirnaty | Pfizer-BioNTech | mRNA | 65+; ages 5-64 with a qualifying condition |
| Spikevax | Moderna | mRNA | 65+; ages 6 months-64 years with a qualifying condition |
| mNEXSPIKE | Moderna | mRNA | 65+; ages 12-64 with a qualifying condition |
| Nuvaxovid | Novavax (commercialized by Sanofi) | Protein subunit | 65+; ages 12-64 with a qualifying condition |
Nuvaxovid remains the only non-mRNA option, for patients who prefer a protein-based vaccine.
Notice the pattern in that right-hand column: the FDA labels for all four products are restricted to adults 65 and older, plus younger people with at least one underlying condition that raises their risk. That’s a carryover from last year’s narrowing, and it’s the source of a lot of the confusion below.
The 2026 Guidance Situation, Explained
This is the part that’s genuinely different from previous years, so bear with us — it’s worth understanding.
Vaccine policy in this country normally runs on two separate tracks:
- The FDA decides whether a vaccine is safe and effective, and what strain it should target. This track worked normally in 2026. Strain picked in May, products approved in August, right on schedule.
- The CDC’s Advisory Committee on Immunization Practices (ACIP) decides who should receive it — and that recommendation is what most insurance coverage, state pharmacy laws, and standing orders have historically been tied to. This track is broken.
ACIP has been without a functioning quorum since March 2026, when a federal court in Massachusetts ruled in American Academy of Pediatrics v. Kennedy that most of the committee’s appointed members were seated improperly. The court stayed those appointments, stayed the votes they had taken, and stayed the revised immunization schedules — effectively reverting federal recommendations to their earlier versions while the case proceeds. The government has appealed, and the case is still unresolved.
The practical upshot: there is an approved, updated vaccine for 2026-2027, and no current federal statement about who should get it.
We want to be clear about something. This is a procedural and legal breakdown, not a scientific one. Nothing about the court case says anything about whether these vaccines work. The strain selection followed the same process we’ve used for decades to pick the annual flu strain. The vaccine in the vial is the vaccine the science called for.
What This Means for New Yorkers
Here’s where it gets better, and where being in New York genuinely matters.
In May 2026, Governor Hochul signed two bills that structurally decouple New York from the federal ACIP process:
- A.10710/S.9599 requires health insurers to cover vaccines recommended by the New York State Commissioner of Health — not just those recommended by ACIP.
- A.10711/S.9598 strips ACIP references out of Public Health Law, Education Law, and Social Services Law, and authorizes pharmacists to administer COVID-19 vaccines to children ages 2 through 18 under state law. Previously, state law only allowed pharmacists to vaccinate adults.
Translation: New York is no longer waiting on a functioning federal committee to decide whether your pharmacist can vaccinate you, or whether your insurance has to cover it. That’s the difference between last year’s emergency executive orders — temporary patches that had to be renewed over and over — and an actual durable fix.
On cost: most people should still pay nothing. Major insurers committed to covering vaccines that were ACIP-recommended as of September 1, 2025 with no cost-sharing through the end of 2027, and New York’s new coverage law adds a state-level backstop. If you hit an unexpected charge at any pharmacy, that’s worth a phone call before you pay it.
Our Recommendations
Who Should Get The 2026-2027 COVID Vaccine?
Given the federal vacuum, we’re doing what most independent pharmacies and professional medical societies are doing: relying on the standards that were in place before the disruption, plus the guidance from New York State and organizations like the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists.
On that basis, here’s who we think should be first in line:
- Adults 65 and older. Highest risk, clearest benefit. This group is squarely within every product’s FDA label.
- Anyone with an underlying condition that increases risk of severe COVID-19 — this is a long list and includes things people don’t always think of, like obesity, diabetes, asthma, heart disease, chronic kidney disease, and pregnancy. Ask us if you’re unsure whether you qualify.
- Moderately to severely immunocompromised individuals, who may benefit from additional doses beyond the standard schedule.
- People who are pregnant or breastfeeding. Pregnancy meaningfully increases the risk of severe COVID-19. Federal recommendations here have swung back and forth over the past two years, which we know has been confusing. The underlying risk hasn’t swung at all. Talk to your OB.
- Children, particularly those with risk factors. New York now explicitly authorizes pharmacists to vaccinate ages 2-18; younger children should see their pediatrician.
- Anyone who lives with or cares for someone in the groups above.
In general, we recommend an updated COVID-19 vaccine once yearly for adults, and twice yearly for elderly or immunocompromised individuals — with the second dose roughly 6 months after the first.
If you don’t fall into any of these categories and you’re weighing whether it’s worth it, that’s a legitimate conversation and we’re happy to have it. Come talk to us.
Who Shouldn’t Get The 2026-2027 COVID Vaccine?
- People with a current COVID-19 infection or another moderate-to-severe illness should wait until they’ve recovered and finished isolating. A minor cold is not a reason to reschedule.
- Anyone with a known severe allergic reaction to a component of the vaccine, or who had a severe allergic reaction to a previous dose of a COVID-19 vaccine. If you reacted to an mRNA product, Nuvaxovid may be an option worth discussing.
- Anyone who’s had a COVID-19 vaccine dose in the last 8 weeks should generally wait out that interval.
Learn More: Vaccine Ingredients in 2026: Less Scary Than You Might Think
When is the Best Time to Get the 2025-2026 COVID Vaccine?
“The short answer is: as soon as you can get it. The doses landed later than usual this year and we’re already in a wave.” — Dr. Neal Smoller
The vaccines were approved August 27 and are shipping now. In a typical year, we’d tell you late August to early September, before Labor Day. This year the approval came so late in August that “before Labor Day” and “as soon as it’s available” are basically the same advice.
Two things push toward not waiting:
There’s already a wave. Wastewater surveillance showed SARS-CoV-2 levels climbing steadily since late June, with August concentrations roughly double July’s. Multiple states are reporting active outbreaks. The fall wave has historically started right after Labor Day, but this year it started early.
Protection takes about two weeks to build after the shot. Getting vaccinated the week your family gets sick is too late to help with that particular exposure.
The one reason to wait: if you’ve had a COVID-19 vaccine in the past 8 weeks, or you’re currently recovering from an infection.
Learn More: Seasonal Vaccination: When Should You Get Your Vaccines in 2026?
Side Note: Are There Side Effects to the COVID Vaccine?
“The most commonly reported side effects after COVID-19 vaccination include mild muscle or joint pain, mild redness and/or swelling of the injection site, potential fever, headache, fatigue, and nausea. The vast majority of these side effects are mild and do not impede daily life in any way.” — Dr. Neal Smoller
Are COVID-19 Vaccines Effective Against XFG?
Short version: yes, and the match this year is a good one.
Unlike some previous seasons where the vaccine was a best guess about where the virus would drift, XFG has been the dominant U.S. variant for months and is expected to remain so or be replaced by close relatives. The 2026-2027 formula is built directly against it.
Interim data from the 2025-2026 season showed vaccine-associated protection against COVID-related emergency department visits and hospitalizations, in both immunocompromised and non-immunocompromised patients. That’s the outcome these vaccines are really designed to prevent.
Two honest caveats:
Protection wanes. That’s why we update annually and why higher-risk patients get a second dose at six months. It’s not a failure of the vaccine; it’s how immunity to respiratory viruses works.
These vaccines reduce severity better than they prevent infection. You can be vaccinated and still catch COVID. The goal was never a forcefield — it’s keeping you out of the hospital.
XFG doesn’t appear to cause more severe illness than earlier Omicron descendants, though it is highly transmissible. One symptom pattern people have reported: a scratchy or hoarse throat that’s easy to write off as allergies. If that’s you and you’ve been around someone sick, test.
COVID Vaccine: Now You’re in the Know
Long story short: the 2026-2027 vaccine is here; it targets the variant that’s actually circulating, and there’s already a wave underway. If you’re 65+, have a risk factor, are pregnant, or care for someone vulnerable, don’t wait for the federal government to sort itself out.
And here in New York, you don’t have to. State law now stands on its own.
But it’s still important to remember that vaccines were never designed to be a forcefield. They are a powerful aid to help prevent dangerous illnesses, but they must be supported by safe and healthy lifestyle choices. Think of them as just one tool in your holistic, or whole-picture, wellness toolbox.
As always, if you need professional guidance to help you navigate the 2026-2027 COVID vaccine season, or direction on developing some other tools for your healthy lifestyle, let’s chat. Our team of experienced vaccine professionals and health advocates is only a call away.